Ticker: REPL

Replimune Group, Inc. (NASDAQ: REPL) is navigating a complex landscape as a clinical-stage biotechnology firm focused on oncolytic immunotherapy to combat cancer. The company is actively conducting several clinical trials for its lead product candidate, RP1, while grappling with significant opera...